Scarica l'app Stockscreener
36.44
3.14%
-1.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$37.62
Aprire:
$37.37
Volume 24 ore:
3.14M
Relative Volume:
0.55
Capitalizzazione di mercato:
$42.46B
Reddito:
$17.53B
Utile/perdita netta:
$1.58B
Rapporto P/E:
27.08
EPS:
1.3457
Flusso di cassa netto:
$444.18M
1 W Prestazione:
-2.41%
1M Prestazione:
+15.06%
6M Prestazione:
+7.62%
1 anno Prestazione:
+102.00%
Intervallo 1D:
$36.37
$37.42
Intervallo di 1 settimana:
$36.37
$38.37
Portata 52W:
$17.94
$38.37
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Nome
Teva Pharmaceutical Industries Ltd Adr
Settore
Telefono
972 (3) 914-8213
Indirizzo
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.44 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
18.03 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.34 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
515.46 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-12-05 | Iniziato | Scotiabank | Sector Outperform |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-05-28 | Iniziato | Truist | Buy |
| 2025-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Aggiornamento | Argus | Hold → Buy |
| 2024-03-08 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-11-27 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-06 | Aggiornamento | UBS | Sell → Neutral |
| 2023-05-25 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | UBS | Neutral → Sell |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-06-14 | Ripresa | UBS | Neutral |
| 2022-05-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Downgrade | Argus | Buy → Hold |
| 2021-10-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Downgrade | UBS | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Iniziato | Oppenheimer | Perform |
| 2020-08-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Ripresa | Goldman | Neutral |
| 2020-06-01 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-24 | Ripresa | Citigroup | Neutral |
| 2020-04-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-02-24 | Downgrade | Edward Jones | Hold → Sell |
| 2019-11-12 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Iniziato | Wolfe Research | Peer Perform |
| 2019-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-07-05 | Aggiornamento | Argus | Hold → Buy |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-06-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Downgrade | UBS | Buy → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-03-07 | Ripresa | UBS | Buy |
Mostra tutto
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm
TEVA Stock Quote Price and Forecast - CNN
Teva receives FDA priority review for Tourette drug - grafa.com
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria
TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan
TEVA Stock Price, Quote & Chart - ChartMill
Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria
Teva stock hits 52-week high at 37.35 USD - Investing.com
Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm
Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar
July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm
Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm
Teva seeks clarity on Trump drug tariff plans, CEO says By Investing.com - Investing.com South Africa
Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment - Investing.com
Teva stock leans on its generic drug base. - Ad-hoc-news.de
883035 Forecast — Price Target — Prediction for 2027 - TradingView
TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
TEV Forecast — Price Target — Prediction for 2027 - TradingView
TEVA Forecast — Price Target — Prediction for 2027 - TradingView
TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Enterprise value to EBITDA forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR - TradingView
Teva Pharmaceutical Industries Limited Sponsored ADR - TradingView
TEVA News | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth - TradingView
Why Is Teva Pharmaceutical (NYSE:TEVA) Drawing NYSE Composite Attention? - Kalkine Media
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback - Sahm
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome - Yahoo Finance
Teva Pharmaceutical Industries Ltd Adr Azioni (TEVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.70%
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):